Skip to content
Companies

Ernexa Therapeutics

Off-the-shelf stem cell therapy for ovarian cancer

Raised to date

$7.2M

of $7.2M offered across 1 Form D filing

Investors
15
Last filed
Apr 11, 2025

About

Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell therapy solutions for advanced cancer and autoimmune diseases. They use induced pluripotent stem cells (iPSCs) to create induced mesenchymal stem cells (iMSCs) with unique targeting capabilities, enabling the creation of scalable, off-the-shelf therapies. This method eliminates the need for patient-specific solutions.

Scalable iPSC-derived iMSC therapies

Funding

  • EquityFiled Apr 11, 2025Form D
    $7.2M/ $7.2M

Product

ERNA-101

Cell Therapy

ERNA-101 is a cell therapy product in development for the treatment of ovarian cancer. It leverages the natural tumor-homing abilities of iMSCs to deliver pro-inflammatory cytokines like IL-7 and IL-15 directly to the tumor microenvironment, enhancing the immune system's ability to target and destroy cancer cells.

  • IMSC-based cell therapy
  • Tumor-homing capabilities
  • Targeted delivery of pro-inflammatory cytokines

Built for

Ovarian Cancer Patients

People on file